Examining LRG Levels to Predict Remission in Ulcerative Colitis
Official title: What is the Level of Serum Leucine-rich α 2-glycoprotein (LRG) Which Predicts Histologic Remission in Patients With Ulcerative Colitis?
Run by Showa Inan General Hospital · NCT06372613 · Data updated 2026-11-12
This study is testing if measuring a specific protein in the blood can help predict when people with ulcerative colitis will go into remission.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 20 Years to 90 Years |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Showa Inan General Hospital Academic / other |
| Locations | 1 site (Komagane) |
| Status | Recruiting |
| Started | February 25, 2024 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | August 13, 2026 |
| Trial ID | NCT06372613 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are patients currently experiencing active ulcerative colitis.
✕Probably not a fit
Patients who are not currently experiencing active ulcerative colitis may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the potential of serum leucine-rich α 2-glycoprotein (LRG) as a noninvasive biomarker for predicting histologic remission in patients with ulcerative colitis (UC). Patients with active UC will have their serum LRG levels measured, and colonoscopy with histology will be performed when histologic remission is anticipated, regardless of symptoms or serum LRG values. The study aims to evaluate the diagnostic ability of LRG through analysis of the area under receiver operating characteristic (ROC) curves, providing insights into disease activity monitoring.
Why it matters
Potential benefit: If successful, this study could provide a reliable noninvasive method for monitoring remission in ulcerative colitis patients.
How similar studies have gone: While the use of biomarkers in ulcerative colitis is an area of ongoing research, this specific approach using LRG is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * definitive UC patients based on the standard criteria Exclusion Criteria: * None
Where it's running
-
Showa Inan General Hospital
Komagane, Japan Recruiting
Study contacts
- Study coordinator: Akia Horiuchi
- Email: horiuchi.akira@sihp.jp
- Phone: 09021684311
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Etrasimod for ulcerative colitis in older adults
This study will test whether etrasimod is safe and helps control active ulcerative colitis in older adults.
-
Comparing two types of catheters for removing bile duct stones
This study tests whether a new type of catheter can remove larger bile duct stones better than the standard catheter for patients with these stones.
-
Evaluating the effects of a traditional Japanese medicine for patients with intestinal cysts
This study is testing a traditional Japanese medicine called TJ-134 to see if it can help people with intestinal cysts feel better over 8 weeks.
-
Bleeding rates in patients on blood thinners undergoing endoscopy
This study looks at how often patients on blood thinners bleed during endoscopy procedures like EGD and colonoscopy to see if it's safe for them to have these tests.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.